Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 155

1.

Phosphospecific flow cytometry for pharmacodynamic drug monitoring: analysis of the JAK-STAT signaling pathway.

Vafadari R, Weimar W, Baan CC.

Clin Chim Acta. 2012 Sep 8;413(17-18):1398-405. doi: 10.1016/j.cca.2011.12.023. Epub 2012 Jan 10. Review.

PMID:
22261016
2.

Pharmacodynamic analysis of tofacitinib and basiliximab in kidney allograft recipients.

Vafadari R, Quaedackers ME, Kho MM, Mol WM, Chan G, Weimar W, Baan CC.

Transplantation. 2012 Sep 15;94(5):465-72. doi: 10.1097/TP.0b013e3182626b5a.

PMID:
22960764
3.

JAK/STAT pathway plays a critical role in the proinflammatory gene expression and apoptosis of RAW264.7 cells induced by trichothecenes as DON and T-2 toxin.

Wang X, Liu Q, Ihsan A, Huang L, Dai M, Hao H, Cheng G, Liu Z, Wang Y, Yuan Z.

Toxicol Sci. 2012 Jun;127(2):412-24. doi: 10.1093/toxsci/kfs106. Epub 2012 Mar 27.

4.

Inhibition of Janus kinase/signal transducer and activator of transcription (JAK/STAT) signalling pathway in rheumatoid synovial fibroblasts using small molecule compounds.

Migita K, Izumi Y, Torigoshi T, Satomura K, Izumi M, Nishino Y, Jiuchi Y, Nakamura M, Kozuru H, Nonaka F, Eguchi K, Kawakami A, Motokawa S.

Clin Exp Immunol. 2013 Dec;174(3):356-63. doi: 10.1111/cei.12190.

5.

Defining the role of the JAK-STAT pathway in head and neck and thoracic malignancies: implications for future therapeutic approaches.

Lai SY, Johnson FM.

Drug Resist Updat. 2010 Jun;13(3):67-78. doi: 10.1016/j.drup.2010.04.001. Epub 2010 May 14. Review.

PMID:
20471303
6.

Therapeutic targeting of the Jak/STAT pathway.

Aittomäki S, Pesu M.

Basic Clin Pharmacol Toxicol. 2014 Jan;114(1):18-23. doi: 10.1111/bcpt.12164. Epub 2013 Nov 15. Review.

7.

Involvement of JAK/STAT signaling in the pathogenesis of inflammatory bowel disease.

Coskun M, Salem M, Pedersen J, Nielsen OH.

Pharmacol Res. 2013 Oct;76:1-8. doi: 10.1016/j.phrs.2013.06.007. Epub 2013 Jul 2. Review.

PMID:
23827161
8.
10.

Small molecule inhibitors of NF-kB and JAK/STAT signal transduction pathways as promising anti-inflammatory therapeutics.

Ivanenkov YA, Balakin KV, Lavrovsky Y.

Mini Rev Med Chem. 2011 Jan;11(1):55-78. Review.

PMID:
21034406
11.

The JAK-STAT pathway: a therapeutic target in hematological malignancies.

Ferrajoli A, Faderl S, Ravandi F, Estrov Z.

Curr Cancer Drug Targets. 2006 Dec;6(8):671-9. Review.

PMID:
17168672
12.

Emerging therapeutic paradigms to target the dysregulated Janus kinase/signal transducer and activator of transcription pathway in hematological malignancies.

Mughal TI, Girnius S, Rosen ST, Kumar S, Wiestner A, Abdel-Wahab O, Kiladjian JJ, Wilson WH, Van Etten RA.

Leuk Lymphoma. 2014 Sep;55(9):1968-79. doi: 10.3109/10428194.2013.863307. Epub 2014 Feb 17. Review.

13.

Model-driven experimental analysis of the function of SHP-2 in IL-6-induced Jak/STAT signaling.

Dittrich A, Quaiser T, Khouri C, Görtz D, Mönnigmann M, Schaper F.

Mol Biosyst. 2012 Aug;8(8):2119-34. doi: 10.1039/c2mb05488d. Epub 2012 Jun 19.

PMID:
22711165
14.

Inhibition of JAK/STAT signaling pathway prevents high-glucose-induced increase in endothelin-1 synthesis in human endothelial cells.

Manea SA, Manea A, Heltianu C.

Cell Tissue Res. 2010 Apr;340(1):71-9. doi: 10.1007/s00441-010-0936-1. Epub 2010 Mar 9.

PMID:
20217138
15.

Human cytokines activate JAK-STAT signaling pathway in porcine ocular tissue.

Fasler-Kan E, Barteneva NS, Ketterer S, Wunderlich K, Reschner A, Nurzhanova A, Flammer J, Huwyler J, Meyer P.

Xenotransplantation. 2013 Nov-Dec;20(6):469-80. doi: 10.1111/xen.12070. Epub 2013 Nov 1.

16.

Mining for JAK-STAT mutations in cancer.

Constantinescu SN, Girardot M, Pecquet C.

Trends Biochem Sci. 2008 Mar;33(3):122-31. doi: 10.1016/j.tibs.2007.12.002. Review.

PMID:
18291658
17.

Engagement of the B-cell antigen receptor activates STAT through Lyn in a Jak-independent pathway.

Wang L, Kurosaki T, Corey SJ.

Oncogene. 2007 May 3;26(20):2851-9. Epub 2006 Dec 4.

PMID:
17146444
18.

Molecular pathways: molecular basis for sensitivity and resistance to JAK kinase inhibitors.

Meyer SC, Levine RL.

Clin Cancer Res. 2014 Apr 15;20(8):2051-9. doi: 10.1158/1078-0432.CCR-13-0279. Epub 2014 Feb 28. Review.

19.

Dynamics and non-canonical aspects of JAK/STAT signalling.

Mohr A, Chatain N, Domoszlai T, Rinis N, Sommerauer M, Vogt M, Müller-Newen G.

Eur J Cell Biol. 2012 Jun-Jul;91(6-7):524-32. doi: 10.1016/j.ejcb.2011.09.005. Epub 2011 Oct 21. Review.

PMID:
22018664
20.

The signal transduction mediated by erythropoietin and proinflammatory cytokines in the JAK/STAT pathway in the children with cerebral palsy.

Tao W, Wen F, Zhang H, Liu G.

Brain Dev. 2009 Mar;31(3):200-7. doi: 10.1016/j.braindev.2008.06.011. Epub 2008 Aug 19. Review.

PMID:
18715729
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk